10:23 AM EDT, 05/06/2024 (MT Newswires) -- Delcath Systems ( DCTH ) said Monday that the results from the pivotal phase 3 study of Hepzato Kit in unresectable metastatic uveal melanoma were published in the Annals of Surgical Oncology journal.

The study, designed to evaluate the efficacy and safety of Hepzato Kit demonstrated a 36.3% overall response rate with 7.7% achieving complete response, surpassing historic data, according to Delcath ( DCTH ).

Secondary endpoints, including duration of response, median progression-free survival, and median overall survival, were 14, 9, and 20.5 months, respectively.

Safety and tolerability data from the phase 3 study were comparable with published clinical experience with Chemosat in Europe, the company said.

Shares of the oncology company were up 2% in recent Monday trading.

Price: 5.68, Change: +0.12, Percent Change: +2.07